Skip to content

Epidemiology and burden

TL;DR — Population surveys place chronic pain with neuropathic characteristics at approximately 6.9–10%, but estimates range from 3–17% because instruments, duration thresholds and confirmation differ (van Hecke 2014, PMID 24291734). Etiology-specific prevalence is more interpretable: neuropathic pain affects about 53% after spinal-cord injury, chemotherapy-induced peripheral neuropathy persists in about 30% at ≥6 months, and the neuropathic component among people with persistent postsurgical pain ranges from 6% after arthroplasty to 66–68% after thoracic or breast surgery (Burke 2017, PMID 27341614; Seretny 2014, PMID 25261162; Haroutiunian 2013, PMID 23273105). Burden is not captured by pain intensity alone: pooled health utilities ranged from 0.15 in failed-back-surgery syndrome to 0.61 in postherpetic neuralgia/diabetic neuropathy and declined with pain severity (Doth 2010, PMID 20227832). Case-definition heterogeneity is the principal obstacle to comparisons.

Population prevalence

The systematic review of 21 general-population studies could not meta-analyze because ascertainment differed; chronic pain with neuropathic characteristics ranged from 3% to 17%, with validated-tool estimates clustering at 6.9–10% (van Hecke 2014, PMID 24291734).

Estimate Population/method Interpretation Source
3–17% General-population studies; mixed definitions Full observed range, not a pooled rate van Hecke 2014, PMID 24291734
6.9–10% Validated screening instruments Best broad estimate of neuropathic characteristics van Hecke 2014, PMID 24291734
43.5% (95% CI 38.4–48.6) UK chronic pain, 7 studies Denominator context; not all neuropathic Fayaz 2016, PMID 27324708
10.4–14.3% UK moderate/severely disabling chronic pain Disability context; mechanism not specified Fayaz 2016, PMID 27324708
10% (95% CI 6–15) Chronic kidney disease, 116 studies Neuropathic-pain subgroup in CKD Lambourg 2021, PMID 33940112

Questionnaire-positive prevalence is not equivalent to definite neuropathic pain. Screening tools privilege sensitivity, whereas NeuPSIG grading requires signs and lesion confirmation (Bouhassira 2019, PMID 30385075; Finnerup 2016, PMID 27115670).

Incidence and prevalence by etiology

Condition Published estimate Population/method Main caveat
Painful diabetic neuropathy 10–20% of people with diabetes; 40–50% of those with diabetic neuropathy Literature synthesis Older heterogeneous studies
Postherpetic neuralgia 3.9–42.0 per 100,000 person-years General-population review Age and definition vary
PHN among zoster cases 5% to >30% 130 studies/26 countries Duration threshold and age mix differ
Chemotherapy-induced neuropathy 68.1% (57.7–78.4) in month 1 31 studies, 4,179 patients Agent and assessment heterogeneity
Chemotherapy-induced neuropathy 60.0% (36.4–81.6) at 3 months Same meta-analysis Wide interval
Chemotherapy-induced neuropathy 30.0% (6.4–53.5) at ≥6 months Same meta-analysis Very wide interval
Neuropathic pain after SCI 53% (38.58–67.47) 17 studies, 2,529 people I² 84–93%
At-level pain after SCI 19% (13.26–26.39) Meta-analysis Definitions vary
Below-level pain after SCI 27% (19.89–34.61) Meta-analysis Definitions vary
Neuropathic pain after SCI 57% (95% CI 51–64) Updated meta-analysis; 24 studies, n=6,318 I²=96.2%; classification system affected prevalence
Below-level pain after SCI 30% Updated subgroup synthesis Classification-dependent
At-level pain after SCI 20% Updated subgroup synthesis Classification-dependent

These groups overlap: diabetes can coexist with chemotherapy exposure; spinal disease can coexist with polyneuropathy; and cancer pain may contain tumor, treatment and postsurgical mechanisms (Colloca 2017, PMID 28205574).

The change from 53% in the 2017 synthesis to 57% in the updated synthesis is not evidence of a temporal increase. The confidence intervals overlap, study sets differ, and the updated meta-regression identified classification system—not age, sex, traumatic etiology, time since injury, injury severity or neurologic level—as a prevalence determinant (Salehian 2025, PMID 41043376). This is a measurement controversy, not a trend.

Persistent postsurgical neuropathic pain

A review of 281 studies across 11 operations found that among patients who already had persistent postsurgical pain, probable/definite neuropathic pain occurred in 68% after breast surgery, 66% after thoracic surgery, 31% after hernia repair and 6% after hip/knee arthroplasty (Haroutiunian 2013, PMID 23273105).

Operation Neuropathic component among persistent pain Likely exposure
Breast surgery 68% Intercostobrachial/pectoral nerve injury
Thoracic surgery 66% Intercostal nerve injury
Groin hernia repair 31% Ilioinguinal/iliohypogastric/genitofemoral injury
Hip/knee arthroplasty 6% Mixed surgical and joint mechanisms

This is a conditional percentage, not incidence among everyone undergoing surgery. Mixing the two denominators exaggerates population risk (Haroutiunian 2013, PMID 23273105). Prospective work also shows that acute pain response and preoperative factors matter, but models remain insufficiently transportable for routine individual prediction (Blichfeldt-Eckhardt 2018, PMID 29510808; Boogaard 2015, PMID 26431122).

Herpes zoster and PHN

Herpes-zoster incidence commonly falls between 3 and 5 per 1,000 person-years across North America, Europe and Asia-Pacific; PHN risk varies from 5% to >30%, and >30% of PHN cases in some studies persisted beyond one year (Kawai 2014, PMID 24916088).

The Shingles Prevention Study randomized 38,546 adults aged ≥60 years: 957 confirmed zoster cases occurred (315 vaccine vs 642 placebo), and 107 PHN cases occurred (27 vs 80) over median 3.12 years (Oxman 2005, PMID 15930418). Post-licensure evidence confirms that vaccine product, dose completion and immune status affect effectiveness (Mbinta 2022, PMID 36098300).

Diabetic neuropathic pain

Pain affects a subset of neuropathy, while advanced sensory loss can be painless but dangerous. Older synthesis estimated painful diabetic neuropathy in 10–20% of people with diabetes and 40–50% of those with neuropathy (Veves 2008, PMID 18828198).

Risk is not glycemia alone. Duration, metabolic syndrome, obesity, dyslipidemia, vascular factors and type of diabetes shape neuropathy, and intensive glucose control prevents neuropathy more consistently in type 1 than type 2 diabetes (Peltier 2014, PMID 24803311; Feldman 2019, PMID 31197153).

A clinical synthesis estimated distal symmetric sensorimotor polyneuropathy in approximately one third of people with diabetes and painful disease in up to one quarter, while noting that as many as half of affected people may be asymptomatic (Ziegler 2020, PMID 32086529). These denominators answer different questions: neuropathy among diabetes, pain among neuropathy, and recognized symptomatic disease must not be substituted for one another.

Central neuropathic pain

SCI has the strongest prevalence synthesis, but central pain also follows stroke and multiple sclerosis. Lesion location, sensory tract injury and case criteria matter more than the broad disease label (Widerström-Noga 2017, PMID 28666966; Rosner 2023, PMID 38129427).

Central post-stroke pain trials remain small: a 2022 network meta-analysis included 13 randomized trials and 529 participants, underscoring how treatment evidence is thin relative to disease burden (Bo 2022, PMID 36035203).

Health utility and quality of life

The health-utility meta-analysis included 24 studies. Mean pooled utility values ranged from 0.15 for failed-back-surgery syndrome to 0.61 for PHN and diabetic neuropathy; severity, rather than diagnostic category or demographic variables, showed the clearest association with lower utility (Doth 2010, PMID 20227832).

Domain Reported consequence Evidence
Sleep Difficulty initiating/maintaining sleep and non-restorative sleep DPNP qualitative study, n=70 (Brod 2015, PMID 25354872)
Mobility Walking, standing, balance and exercise limitations DPNP qualitative study, n=70 (Brod 2015, PMID 25354872)
Work/productivity Reduced concentration, chores, recreation and work DPNP qualitative study, n=70 (Brod 2015, PMID 25354872)
Emotional function Fear, anxiety, irritability and depression themes DPNP qualitative study, n=70 (Brod 2015, PMID 25354872)
Daily living 9/10 affected in an Argentina zoster/PHN sample Belizan 2024, PMID 39232368
Sleep in HZ/PHN 7/10 affected in that sample Belizan 2024, PMID 39232368

Qualitative samples provide depth, not prevalence. The n=70 diabetic study required pain ≥4/10 and therefore describes a symptomatic subgroup; the Argentina study interviewed only 10 participants (Brod 2015, PMID 25354872; Belizan 2024, PMID 39232368).

Treatment and system burden

Average pharmacologic effects are modest: NeuPSIG calculated NNTs for 50% relief of 6.4 for SNRIs, 7.2 for gabapentin, 7.7 for pregabalin and 10.6 for high-concentration capsaicin (Finnerup 2015, PMID 25575710). Consequently, serial trials, adverse effects and discontinuation are part of the burden rather than merely treatment details.

Health-system estimates are difficult to compare because studies variously count medication, consultations, procedures, productivity loss and informal care. The broader chronic-pain literature also shows unequal access and opioid-related harm, which complicate attribution to neuropathic pain alone (Cohen 2021, PMID 34062143).

Sources of epidemiologic distortion

Distortion Direction of bias
Symptom questionnaire without lesion confirmation Usually inflates neuropathic classification
Specialist-clinic recruitment Enriches severe/refractory disease
Claims-code studies Miss undiagnosed cases and inherit coding errors
Short PHN duration threshold Raises PHN frequency
Cross-sectional chemotherapy assessment Mixes acute and persistent neuropathy
Reporting pain among neuropathy rather than diabetes Changes denominator by several-fold
Failure to separate pain from numbness Conflates painful and painless neuropathy
Survivor-only cohorts Under-represent treatment discontinuation and death

Quantified instrument effects

Instrument validation illustrates how distortion arises. The original paper painDETECT study reported 85% sensitivity and 80% specificity in chronic low-back pain and classified 37% of an unselected back-pain cohort as predominantly neuropathic (Freynhagen 2006, PMID 17022849). By contrast, community S-LANSS validation against clinical assessment found mailed sensitivity 57% (95% CI 46–69%) and specificity 69% (61–77%), while telephone sensitivity was 52% (39–64%) and specificity 78% (68–85%) (Weingarten 2007, PMID 17869424). Even before lesion confirmation, the same underlying population could therefore yield meaningfully different apparent prevalence according to instrument and administration mode.

The epidemiologic hierarchy is consequently:

  1. representative sampling with lesion-based probable/definite grading;
  2. representative sampling with clinician adjudication;
  3. representative sampling with a validated screening instrument;
  4. administrative codes or convenience cohorts;
  5. symptom descriptors without anatomical confirmation.

Lower tiers remain useful for surveillance and hypothesis generation, but uncertainty should widen rather than disappear when sample size increases.

Open questions

  • What is the prevalence of probable/definite neuropathic pain in representative populations examined under the 2016 grading system? (van Hecke 2014, PMID 24291734; Finnerup 2016, PMID 27115670)
  • Which neuropathic etiologies contribute most to disability-adjusted burden when competing comorbidity is modeled explicitly? (Doth 2010, PMID 20227832)
  • Why does persistent CIPN prevalence remain near 30% at ≥6 months, and which baseline factors identify the durable phenotype? (Seretny 2014, PMID 25261162)
  • Can harmonized postsurgical definitions produce procedure-specific absolute risks rather than conditional percentages? (Haroutiunian 2013, PMID 23273105)
  • How much population PHN burden is preventable with complete recombinant-zoster vaccination across immune-status strata? (Mbinta 2022, PMID 36098300)

References

  1. van Hecke O, et al. Neuropathic pain in the general population: systematic review. Pain. 2014;155:654-662. PMID 24291734
  2. Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Rev Neurol. 2019;175:16-25. PMID 30385075
  3. Finnerup NB, et al. Updated neuropathic-pain grading system. Pain. 2016;157:1599-1606. PMID 27115670
  4. Fayaz A, et al. Prevalence of chronic pain in the UK: systematic review and meta-analysis. BMJ Open. 2016;6:e010364. PMID 27324708
  5. Lambourg E, et al. Prevalence of pain among patients with chronic kidney disease. Kidney Int. 2021;100:636-649. PMID 33940112
  6. Doth AH, et al. Burden of neuropathic pain: meta-analysis of health utilities. Pain. 2010;149:338-344. PMID 20227832
  7. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008;9:660-74. PMID 18828198
  8. Peltier A, et al. Painful diabetic neuropathy. BMJ. 2014;348:g1799. PMID 24803311
  9. Feldman EL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:41. PMID 31197153
  10. Seretny M, et al. Incidence, prevalence and predictors of chemotherapy-induced peripheral neuropathy. Pain. 2014;155:2461-2470. PMID 25261162
  11. Burke D, et al. Neuropathic pain prevalence following spinal cord injury. Eur J Pain. 2017;21:29-44. PMID 27341614
  12. Widerström-Noga E, et al. AAPT diagnostic criteria for central neuropathic pain. J Pain. 2017;18:1417-1426. PMID 28666966
  13. Rosner J, et al. Central neuropathic pain. Nat Rev Dis Primers. 2023;9:73. PMID 38129427
  14. Bo Z, Jian Y, Yan L, et al. Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis. Oxid Med Cell Longev. 2022;2022:3511385. PMID 36035203
  15. Haroutiunian S, et al. Neuropathic component in persistent postsurgical pain. Pain. 2013;154:95-102. PMID 23273105
  16. Blichfeldt-Eckhardt MR. From acute to chronic postsurgical pain. Dan Med J. 2018;65:B5326. PMID 29510808
  17. Boogaard S, et al. Predictors of persistent neuropathic pain: systematic review. Pain Physician. 2015;18:433-457. PMID 26431122
  18. Kawai K, et al. Incidence and complications of herpes zoster: systematic review. BMJ Open. 2014;4:e004833. PMID 24916088
  19. Oxman MN, et al. Vaccine to prevent herpes zoster and postherpetic neuralgia. N Engl J Med. 2005;352:2271-2284. PMID 15930418
  20. Mbinta JF, et al. Post-licensure zoster vaccine effectiveness. Lancet Healthy Longev. 2022;3:e263-e275. PMID 36098300
  21. Brod M, et al. Burden of illness of diabetic peripheral neuropathic pain. Patient. 2015;8:339-348. PMID 25354872
  22. Belizan M, Augustovski F, Bardach A, et al. Patient Experience of Herpes Zoster Disease in Argentina: Validation of a Health-Related Quality of Life Conceptual Model. Value Health Reg Issues. 2024;44:101044. PMID 39232368
  23. Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults. Lancet Neurol. 2015;14:162-173. PMID 25575710
  24. Cohen SP, et al. Chronic pain: burden, best practices and advances. Lancet. 2021;397:2082-2097. PMID 34062143
  25. Colloca L, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. PMID 28205574
  26. Salehian F, et al. Prevalence of neuropathic pain following spinal cord injury: An updated systematic review and meta-analysis. J Clin Neurosci. 2025;142:111660. PMID 41043376
  27. Ziegler D. Diabetic polyneuropathy. Internist (Berl). 2020;61:243-253. PMID 32086529
  28. Freynhagen R, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911-1920. PMID 17022849
  29. Weingarten TN, et al. Validation of the S-LANSS in the community setting. Pain. 2007;132:189-194. PMID 17869424